PDB22 EVALUATING THE LONG-TERM COST-EFFECTIVENESS OF INSULIN ASPART (NOVORAPID®) VERSUS HUMAN SOLUBLE INSULIN IN PATIENTS WITHTYPE 2 DIABETES IN SPAIN AND ITALY
Nov 1, 2007, 00:00
10.1016/S1098-3015(10)64970-4
https://www.valueinhealthjournal.com/article/S1098-3015(10)64970-4/fulltext
Title :
PDB22 EVALUATING THE LONG-TERM COST-EFFECTIVENESS OF INSULIN ASPART (NOVORAPID®) VERSUS HUMAN SOLUBLE INSULIN IN PATIENTS WITHTYPE 2 DIABETES IN SPAIN AND ITALY
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)64970-4&doi=10.1016/S1098-3015(10)64970-4
First page :
Section Title :
Open access? :
No
Section Order :
129